3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Smoking Cessation
6
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Tobacco Use Disorder
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
2
Vaping
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Tobacco Use
1
Tobacco Smoking
1
Substance-Related Disorders
1
Stomach Neoplasms
1
Smoking
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Interventions
Nivolumab
146
Ipilimumab
137
pembrolizumab
122
Cyclophosphamide
78
Interleukin-2
69
aldesleukin
63
Temozolomide
46
trametinib
37
Radiosurgery
37
Vemurafenib
36
fludarabine
34
Biopsy
34
dabrafenib
33
Radiotherapy
33
Blood Specimen Collection
31
fludarabine phosphate
30
sargramostim
27
Bevacizumab
27
Introns
23
Dacarbazine
22
Magnetic Resonance Spectroscopy
21
Specimen Handling
20
CTLA-4 Antigen
20
encorafenib
19
cobimetinib
19
binimetinib
19
Paclitaxel
19
Granulocyte-Macrophage Colony-Stimulating Factor
19
Cisplatin
17
incomplete Freund's adjuvant
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Melanoma
×
Nicotine Replacement Therapy
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled